Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Guardant360 CDx Approved in Japan for Utilization in Advanced Solid Tumors

March 16th 2022

The Ministry of Health, Labour, and Welfare has approved Guardant360 CDx to perform comprehensive genomic profiling in patients with advanced solid cancers.

Ross Reflects on Surgical Advances and Changing Trends in CRC

March 10th 2022

Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.

Dr. Jeyarajah on SIR-Spheres® Y-90 Resin Microspheres as Maintenance in CRC With Liver Metastases

March 7th 2022

Rohan Jeyarajah, MD, discusses the potential role of SIR-Spheres® Y-90 resin microspheres from Sirtex Medical in colorectal cancer with liver metastases.

Dr. Hong on Objectives of the CodeBreaK 101 Trial in CRC

March 2nd 2022

David S. Hong, MD, discusses the primary objective of the ongoing phase 1/2 CodeBreaK 101 trial in mutated advanced colorectal cancer and other solid tumors harboring KRAS G12C mutations.

BI 836880/Ezabenlimab Combo Had Limited Antitumor Activity, But Manageable Safety in Advanced MSS CRC

March 2nd 2022

The VEGF/Ang2–targeting bispecific nanobody BI 836880, in combination with ezabenlimab, produced antitumor activity found to be comparable to that of available third-line therapy options in patients with advanced microsatellite stable colorectal cancer.

FDA Places Clinical Hold on KEYNOTE-B79 Trial Examining CAR T-cell Therapy CYAD-101 in Metastatic CRC

March 2nd 2022

The FDA has placed a clinical hold on the phase 1b CYAD-101-002 trial, which is examining the safety and clinical activity of the investigational CAR T-cell therapy CYAD-101 given concurrently with FOLFOX and followed by pembrolizumab in patients with unresectable metastatic colorectal cancer.

Dr. Kopetz on the Utilization of ctDNA in CRC

March 1st 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the utilization of circulating tumor DNA in colorectal cancer.

Dr. Raghav on the Utilization of ctDNA in mCRC

February 25th 2022

Kanwal P.S. Raghav, MBBS, MD, discusses on the utilization of circulating tumor DNA in metastatic colorectal cancer.

Dr. Barzi on Utilizing VEGF Inhibitors Plus Immunotherapy in MSS mCRC

February 24th 2022

Afsaneh Barzi, MD, PhD, discusses the combination of VEGF inhibitors and immunotherapy in microsatellite stable metastatic colorectal cancer.

Dr. Abrams on Next Steps for Cabozantinib/Atezolizumab Combo in MSS/MMRp CRC

February 23rd 2022

Thomas A. Abrams, MD, discusses the next steps for exploration of cabozantinib plus atezolizumab in the treatment of microsatellite stable and mismatch repair proficient colorectal cancer.

Nivolumab Plus SOC Misses PFS End Point of CheckMate-9X8 Trial, But Provides Notable Benefit in Select mCRC Subsets

February 18th 2022

Heinz-Josef Lenz, MD, discusses the safety and efficacy of nivolumab plus standard of care in patients with metastatic colorectal cancer, shares additional insight from the CheckMate-9X8 trial, and alludes to next steps with further exploring the regimen in specific subsets who appear to derive benefit from this approach.

Rapid Readout: ctDNA Dynamics and Clinical Outcomes in the Adjuvant Management of Colorectal Cancer (GALAXY Study)

February 18th 2022

Insight on the observational GALAXY study, which analyzed the relationship between circulating tumor DNA and clinical outcomes in the adjuvant management of colorectal cancer.

Cabozantinib/Atezolizumab Combo Demonstrates Promising Clinical Activity in mCRC

February 18th 2022

Thomas A. Abrams, MD, discusses the ongoing phase 1b COSMIC-021 trial examining cabozantinib/atezolizumab, the efficacy and safety demonstrated with the regimen in those with colorectal cancer, and the next steps for research

Dr. Azzi on the Utilization of the Signatera ctDNA Assay in the CIRCULATE-US Trial in CRC

February 4th 2022

Georges Azzi, MD, co-director, Department of Hematology/Oncology, Prostate Cancer, Holy Cross Health, discusses the utilization of the Signatera circulating tumor DNA assay in the ongoing phase 2/3 CIRCULATE-US trial in colorectal cancer.

Dr. Ross Discusses Advances in Recognizing, Screening, and Treating CRC

February 3rd 2022

Howard M. Ross, MD, discusses advances in recognizing, screening, and treating patients with colorectal cancer.

Dr. Raghav on Potential Combinations With Trastuzumab Deruxtecan in HER2+ CRC

January 28th 2022

Kanwal P.S. Raghav, MBBS, MD, discusses potential combinations with fam-trastuzumab deruxtecan-nxki in HER2-positive colorectal cancer.

Dr. Kopetz the Current State of ctDNA Testing in CRC

January 27th 2022

Edmund Scott Kopetz, MD, PhD, FACP, discusses the current state of circulating tumor DNA testing in colorectal cancer.

Future Directions for mCRC Management

January 27th 2022

Gerald Prager, MD; Chiara Cremolini, MD, PhD; and Tanios S. Bekaii-Saab, MD, review emerging strategies and the future treatment landscape for metastatic colorectal cancer.

Sequencing Therapy for Relapsed mCRC

January 27th 2022

Gerald Prager, MD, leads the discussion on sequencing strategies for patients with relapsed mCRC, including those not previously treated with anti-EGFR inhibitors.

Management of Relapsed mCRC

January 27th 2022

Gerald Prager, MD, and Chiara Cremolini, MD, PhD, share their approach to managing the case of a 72-year-old man with mCRC disease progression and provide insight on rechallenging patients with anti-EGFR regimens.